O-026Results of REARRANGE trial: A randomized phase 2 study comparing different dosing approaches for regorafenib (REG) during the first cycle of treatment in patients (pts) with metastatic colorectal cancer (mCRC). (2nd July 2019) - Argiles, G; Margalef, N Mulet; Valladares-Ayerbes, M; de Prado, J Vieitez; Grávalos, C; Alfonso, P García; Santos, C; Tobeña, M; Sastre, J; Benavides, M; Cano, T; Loupakis, F; et al.